Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Incyte (INCY) Sell-Off on Opzelura Miss an 'Overreaction' - Truist
August 2, 2022 12:45 PM EDTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $95.00 price target on Incyte (NASDAQ: INCY), saying the stock pullback from the Opzelura miss is an overreaction.
The analyst commented, "While JAKAFI beat cons ($598M vs. $587M), stock weak on... More
Incyte (INCY) Tops Q2 EPS by 45c
August 2, 2022 7:08 AM EDTIncyte (NASDAQ: INCY) reported Q2 EPS of $1.01, $0.45 better than the analyst estimate of $0.56. Revenue for the quarter came in at $911 million versus the consensus estimate of $814.9 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
... More